Americans Ready To Crack Down On Drug Prices That Force Some To Skip Doses
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
Pharma Execs Dig In For A Fight Against Outraged Senators
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Congress Squares Off With Pharma CEOs In Showdown Over High Drug Prices
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
Talk About Déjà Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
False Lead: Senator’s Offer To Help Patient Import Cheap Insulin Goes Nowhere
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds Aren’t For Sale
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
Winners And Losers Under Bold Trump Plan To Slash Drug Rebate Deals
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Chronically Ill, Traumatically Billed: The $123,000 Medicine For MS
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
High-Deductible Health Plans Fall From Grace In Employer-Based Coverage
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.
Putting Oversized Health Care Costs Upfront — On T-Shirts
The Maryland Health Care Commission has created a consumer education campaign that puts the costs of common health care procedures on a place where people might see them – T-shirts.
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
States Looking To Tax Opioids Pin Hopes On November Elections
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
As An Investor In Biotech Stock, Republican Chris Collins May Have Overshared
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
Drug Trade Group Quietly Spends ‘Dark Money’ To Sway Policy And Voters
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Administration Eases Way For Small Businesses To Buy Insurance In Bulk
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.”
Why Did Novartis Pay Trump’s Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
As Proton Centers Struggle, A Sign Of A Health Care Bubble?
Companies pushed proton machines and counted on advertising, doctors and insurers to ensure a steady business treating cancer. But the dollars haven’t flowed in as expected.
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
